# Dyne Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dyne-therapeutics

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.dyne-tx.com
- Total disclosed funding: $128M
- Latest round: Series B (Aug 7, 2020)
- Investors on record: 8

## About

Based in Massachusetts, US, and founded in 2018 and led by CEO John Cox, operates as a provider of biotechnology platform that develops and provides muscle-targeted therapies to treat patients with muscle diseases such as myotonic dystrophy type 1. In May 2024, Dyne Therapeutics Inc. raised USD 325.5 million in a private placement, selling 10.5 million shares at USD 31 per share on the NASDAQ under the ticker symbol "DYN". Dyne Therapeutics Inc. has granted the underwriters a 30-day option to purchase up to an additional 1.57 million shares of common stock. 

Dyne Therapeutics Inc. provides muscle-targeted therapies in the biopharmaceutical field. The company’s pipeline includes promising clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), with a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). In addition, the firm offers preclinical data from the FORCE platform in delivering enzyme replacement therapy to muscle and the central nervous system in Pompe disease.

## Funding rounds

- Series B, Aug 7, 2020, $116M — Atlas Venture, Wellington Management, Forbion, MPM BioImpact, Surveyor Capital, Franklin Templeton, Vida Ventures, Logos Capital
- Series A, Dec 5, 2018, $13M — Atlas Venture, Forbion, MPM BioImpact
- Seed, date not disclosed — Atlas Venture

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Seed, Series A, Series B
- Forbion (https://capitalatlas.ai/funds/forbion) — Series A, Series B
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A, Series B
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series B
- Surveyor Capital — Series B
- Franklin Templeton (https://capitalatlas.ai/funds/franklin-templeton) — Series B
- Vida Ventures (https://capitalatlas.ai/funds/vida-ventures) — Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B